<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39457005</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11224</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252011224</ELocationID><Abstract><AbstractText>Pancreatic cancer is one of the deadliest cancers globally, with limited success from existing therapies, including chemotherapies and immunotherapies like checkpoint inhibitors for patients with advanced pancreatic ductal adenocarcinoma (PDAC). A promising new approach is the use of oncolytic viruses (OV), a form of immunotherapy that has been demonstrated clinical effectiveness in various cancers. Here we investigated the potential of the oncolytic coxsackievirus B3 strain (CVB3) PD-H as a new treatment for pancreatic cancer. In vitro, PD-H exhibited robust replication, as measured by plaque assays, and potent lytic activity, as assessed by XTT assays, in most pancreatic tumor cell lines, outperforming two other coxsackievirus strains tested, H3N-375/1TS and CVA21. Thus, H3N-375/1TS showed efficient replication and lytic efficiency in distinctly fewer tumor cell lines, while most tumor cells were resistant to CVA21. The oncolytic efficiency of the three OV largely correlated with mRNA expression levels of viral receptors and their ability to induce apoptosis, as measured by cleaved caspase 3/7 activity in the tumor cells. In a syngeneic mouse model with subcutaneous pancreatic tumors, intratumoral administration of PD-H significantly inhibited tumor growth but did not completely stop tumor progression. Importantly, no virus-related side effects were observed. Although pancreatic tumors respond to PD-H treatment, its therapeutic efficacy is limited. Combining PD-H with other treatments, such as those aiming at reducing the desmoplastic stroma which impedes viral infection and spread within the tumor, may enhance its efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geisler</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieringer</LastName><ForeName>Babette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsner</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klopfleisch</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6308-0568</Identifier><AffiliationInfo><Affiliation>Institute of Veterinary Pathology, Freie Universität Berlin, 14163 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurreck</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1469-0052</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fechner</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7082-4350</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>536819681</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country /></Grant><Grant><GrantID>VAL121/2023</GrantID><Agency>IBB Business Team GmbH program ProValid</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="Y">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVA21</Keyword><Keyword MajorTopicYN="N">KPC cells</Keyword><Keyword MajorTopicYN="N">PD-H</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword><Keyword MajorTopicYN="N">pancreatic cancer</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457005</ArticleId><ArticleId IdType="pmc">PMC11508574</ArticleId><ArticleId IdType="doi">10.3390/ijms252011224</ArticleId><ArticleId IdType="pii">ijms252011224</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0155</ArticleId><ArticleId IdType="pubmed">24840647</ArticleId></ArticleIdList></Reference><Reference><Citation>Masiak-Segit W., Rawicz-Pruszyński K., Skórzewska M., Polkowski W.P. Surgical treatment of pancreatic cancer. Pol. J. Surg. 2018;90:45–53. doi: 10.5604/01.3001.0011.7493.</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/01.3001.0011.7493</ArticleId><ArticleId IdType="pubmed">29773761</ArticleId></ArticleIdList></Reference><Reference><Citation>Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. J. Am. Med. Assoc. 2010;304:1073–1081. doi: 10.1001/jama.2010.1275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.1275</ArticleId><ArticleId IdType="pubmed">20823433</ArticleId></ArticleIdList></Reference><Reference><Citation>Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997;15:2403–2413. doi: 10.1200/JCO.1997.15.6.2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.1997.15.6.2403</ArticleId><ArticleId IdType="pubmed">9196156</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.-L., Gourgou-Bourgade S., de la Fouchardière C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Eng. J. Med. 2011;364:1817–1825. doi: 10.1056/NEJMoa1011923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011923</ArticleId><ArticleId IdType="pubmed">21561347</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas F., Sen F., Keskin S., Kilic L., Yildiz I. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Mol. Clin. Oncol. 2013;1:788–792. doi: 10.3892/mco.2013.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mco.2013.131</ArticleId><ArticleId IdType="pmc">PMC3916173</ArticleId><ArticleId IdType="pubmed">24649248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B., Gibbs P. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. J. Pers. Med. 2019;9:20. doi: 10.3390/jpm9020020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm9020020</ArticleId><ArticleId IdType="pmc">PMC6616860</ArticleId><ArticleId IdType="pubmed">31035449</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplicka A., Lachota M., Pączek L., Zagożdżon R., Kaleta B. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence. Cells. 2024;13:101. doi: 10.3390/cells13010101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13010101</ArticleId><ArticleId IdType="pmc">PMC10777940</ArticleId><ArticleId IdType="pubmed">38201305</ArticleId></ArticleIdList></Reference><Reference><Citation>Laface C., Memeo R., Maselli F.M., Santoro A.N., Iaia M.L., Ambrogio F., Laterza M., Cazzato G., Guarini C., De Santis P., et al. Immunotherapy and Pancreatic Cancer: A Lost Challenge? Life. 2023;13:1482. doi: 10.3390/life13071482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13071482</ArticleId><ArticleId IdType="pmc">PMC10381818</ArticleId><ArticleId IdType="pubmed">37511856</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulart M.R., Stasinos K., Fincham R.E.A., Delvecchio F.R., Kocher H.M. T cells in pancreatic cancer stroma. World J. Gastroenterol. 2021;27:7956–7968. doi: 10.3748/wjg.v27.i46.7956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i46.7956</ArticleId><ArticleId IdType="pmc">PMC8678814</ArticleId><ArticleId IdType="pubmed">35046623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosein A.N., Brekken R.A., Maitra A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 2020;17:487–505. doi: 10.1038/s41575-020-0300-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0300-1</ArticleId><ArticleId IdType="pmc">PMC8284850</ArticleId><ArticleId IdType="pubmed">32393771</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanivelu L., Liu C.-H., Lin L.-T. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front. Immunol. 2022;13:1038226. doi: 10.3389/fimmu.2022.1038226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1038226</ArticleId><ArticleId IdType="pmc">PMC9899992</ArticleId><ArticleId IdType="pubmed">36755812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman H.L., Kohlhapp F.J., Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discov. 2015;14:642–662. doi: 10.1038/nrd4663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4663</ArticleId><ArticleId IdType="pmc">PMC7097180</ArticleId><ArticleId IdType="pubmed">26323545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Hu C., Liu Y., Chen X., Song D., Shen R., Liu Z., Jia X., Zhang Q., Gao Y., et al. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile. Nat. Commun. 2023;14:3410. doi: 10.1038/s41467-023-39156-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39156-3</ArticleId><ArticleId IdType="pmc">PMC10256765</ArticleId><ArticleId IdType="pubmed">37296165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochiai H., Moore S.A., Archer G.E., Okamura T., Chewning T.A., Marks J.R., Sampson J.H., Gromeier M. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res. 2004;10:4831–4838. doi: 10.1158/1078-0432.CCR-03-0694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-03-0694</ArticleId><ArticleId IdType="pubmed">15269159</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan L., Vallath S., Gros A., Giménez-Alejandre M., van Rooijen N., Thomas G.J., Baker A.H., Cascalló M., Alemany R., Hart I.R. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum. Gene Ther. 2012;23:960–979. doi: 10.1089/hum.2011.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2011.218</ArticleId><ArticleId IdType="pubmed">22708837</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S., Inoue H., Nakamura T., Yamada M., Sakamoto C., Urata Y., Okazaki T., Marumoto T., Takahashi A., Takayama K., et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609–2621. doi: 10.1158/0008-5472.CAN-11-3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3185</ArticleId><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Noser J.A., Mael A.A., Sakuma R., Ohmine S., Marcato P., Lee P.W., Ikeda Y. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells. Mol. Ther. 2007;15:1531–1536. doi: 10.1038/sj.mt.6300193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300193</ArticleId><ArticleId IdType="pubmed">17505473</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar-Zarate D., Liu Y.-P., Suksanpaisan L., Russell S.J., Peng K.-W. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther. 2013;20:582–589. doi: 10.1038/cgt.2013.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2013.55</ArticleId><ArticleId IdType="pmc">PMC4817541</ArticleId><ArticleId IdType="pubmed">24030211</ArticleId></ArticleIdList></Reference><Reference><Citation>Achard C., Boisgerault N., Delaunay T., Roulois D., Nedellec S., Royer P.-J., Pain M., Combredet C., Mesel-Lemoine M., Cellerin L., et al. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget. 2015;6:44892–44904. doi: 10.18632/oncotarget.6285.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6285</ArticleId><ArticleId IdType="pmc">PMC4792599</ArticleId><ArticleId IdType="pubmed">26539644</ArticleId></ArticleIdList></Reference><Reference><Citation>Moerdyk-Schauwecker M., Shah N.R., Murphy A.M., Hastie E., Mukherjee P., Grdzelishvili V.Z. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling. Virology. 2013;436:221–234. doi: 10.1016/j.virol.2012.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.11.014</ArticleId><ArticleId IdType="pmc">PMC3544977</ArticleId><ArticleId IdType="pubmed">23246628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann D., Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther. 2007;14:627–639. doi: 10.1038/sj.cgt.7701055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cgt.7701055</ArticleId><ArticleId IdType="pubmed">17479104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi-Sofiani V., Rakhshi R., Moradi N., Zeynali P., Nakhaie M., Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treat. Res. Commun. 2022;31:100563. doi: 10.1016/j.ctarc.2022.100563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctarc.2022.100563</ArticleId><ArticleId IdType="pubmed">35460973</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoidingjam S., Bhatnagar A.R., Sriramulu S., Siddiqui F., Nyati S. Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses. Int. J. Mol. Sci. 2024;25:9912. doi: 10.3390/ijms25189912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25189912</ArticleId><ArticleId IdType="pmc">PMC11432658</ArticleId><ArticleId IdType="pubmed">39337402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajda J., Leuchs B., Angelova A.L., Frehtman V., Rommelaere J., Mertens M., Pilz M., Kieser M., Krebs O., Dahm M., et al. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2021;27:5546–5556. doi: 10.1158/1078-0432.CCR-21-1020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-1020</ArticleId><ArticleId IdType="pubmed">34426438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A., Liu H., Mohamud Y., Xue Y.C., Zhang J., Luo H. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice. Cancer Lett. 2022;548:215849. doi: 10.1016/j.canlet.2022.215849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.215849</ArticleId><ArticleId IdType="pubmed">35995138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Pryshliak M., Brückner V., Klingel K., Sauter M., Pinkert S., Kurreck J., Fechner H. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Hum. Gene Ther. 2018;29:1301–1314. doi: 10.1089/hum.2018.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.036</ArticleId><ArticleId IdType="pubmed">29739251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Wang W., Wan J., Yang Y., Fu W., Pan D., Cai L., Cheng T., Huang X., Wang Y. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virol. J. 2018;15:65. doi: 10.1186/s12985-018-0975-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-018-0975-x</ArticleId><ArticleId IdType="pmc">PMC5891967</ArticleId><ArticleId IdType="pubmed">29631630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Miyamoto S., Soda Y., Takishima Y., Sagara M., Liao J., Hirose L., Hijikata Y., Miura Y., Hara K., et al. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3. Mol. Ther. Oncolytics. 2019;12:246–258. doi: 10.1016/j.omto.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.01.003</ArticleId><ArticleId IdType="pmc">PMC6406029</ArticleId><ArticleId IdType="pubmed">30891489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Dieringer B., Pryshliak M., Knoch K.-P., Heimann L., Tolksdorf B., Pappritz K., El-Shafeey M., Solimena M., Beling A., et al. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity but Strong Antitumor Efficiency in Colorectal Carcinomas. Hum. Gene Ther. 2021;32:216–230. doi: 10.1089/hum.2020.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.228</ArticleId><ArticleId IdType="pubmed">33481658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Dieringer B., Klingel K., Pryshliak M., Geisler A., Kobelt D., Daberkow O., Kurreck J., van Linthout S., Fechner H. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses. 2021;13:1918. doi: 10.3390/v13101918.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13101918</ArticleId><ArticleId IdType="pmc">PMC8539752</ArticleId><ArticleId IdType="pubmed">34696348</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Xue Y.C., Deng H., Mohamud Y., Ng C.S., Chu A., Lim C.J., Lockwood W.W., Jia W.W.G., Luo H. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer. Mol. Ther. Oncolytics. 2020;16:207–218. doi: 10.1016/j.omto.2020.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.01.002</ArticleId><ArticleId IdType="pmc">PMC7036525</ArticleId><ArticleId IdType="pubmed">32123721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A.E., Jahn B., Hammerschmidt E., Wutzler P., Schmidtke M. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J. Virol. 2006;80:6629–6636. doi: 10.1128/JVI.01988-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01988-05</ArticleId><ArticleId IdType="pmc">PMC1488958</ArticleId><ArticleId IdType="pubmed">16775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A.E., Korner U., Henke A., Badorff C., Schmidtke M. Heparan sulfates and coxsackievirus-adenovirus receptor: Each one mediates coxsackievirus B3 PD infection. J. Virol. 2003;77:10071–10077. doi: 10.1128/JVI.77.18.10071-10077.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.18.10071-10077.2003</ArticleId><ArticleId IdType="pmc">PMC224569</ArticleId><ArticleId IdType="pubmed">12941917</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996;70:7811–7818. doi: 10.1128/jvi.70.11.7811-7818.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.11.7811-7818.1996</ArticleId><ArticleId IdType="pmc">PMC190851</ArticleId><ArticleId IdType="pubmed">8892902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S., Jakes A.D., Harrington K., Pandha H., Melcher A., Errington-Mais F. Applications of coxsackievirus A21 in oncology. Oncolytic Virother. 2014;3:47–55. doi: 10.2147/OV.S56322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S56322</ArticleId><ArticleId IdType="pmc">PMC4918364</ArticleId><ArticleId IdType="pubmed">27512662</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels N.E., Mansfield D., Arif M., Ballesteros-Merino C., Simpson G.R., Denyer M., Sandhu S.S., Melcher A.A., Harrington K.J., Davies B., et al. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clin. Cancer Res. 2019;25:5818–5831. doi: 10.1158/1078-0432.CCR-18-4022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-4022</ArticleId><ArticleId IdType="pubmed">31273010</ArticleId></ArticleIdList></Reference><Reference><Citation>Andtbacka R.H.I., Curti B.D., Kaufman H., Daniels G.A., Nemunaitis J.J., Spitler L.E., Hallmeyer S., Lutzky J., Schultz S.M., Whitman E.D., et al. Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. J. Clin. Oncol. 2015;33:9030. doi: 10.1200/jco.2015.33.15_suppl.9030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2015.33.15_suppl.9030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–483. doi: 10.1016/j.ccr.2005.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2005.04.023</ArticleId><ArticleId IdType="pubmed">15894267</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo N., Miller D.M., Haq R., Kaufman H.L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 2020;8:e001486. doi: 10.1136/jitc-2020-001486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001486</ArticleId><ArticleId IdType="pmc">PMC7552841</ArticleId><ArticleId IdType="pubmed">33046622</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A., Hazini A., Heimann L., Kurreck J., Fechner H. Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses. 2021;13:718. doi: 10.3390/v13050718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050718</ArticleId><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Eissa I.R., Bustos-Villalobos I., Ichinose T., Matsumura S., Naoe Y., Miyajima N., Morimoto D., Mukoyama N., Zhiwen W., Tanaka M., et al. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers. 2018;10:356. doi: 10.3390/cancers10100356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers10100356</ArticleId><ArticleId IdType="pmc">PMC6210336</ArticleId><ArticleId IdType="pubmed">30261620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell R., Delwart E., Gorbalenya A.E., Hovi T., King A.M.Q., Knowles N.J., Lindberg A.M., Pallansch M.A., Palmenberg A.C., Reuter G., et al. ICTV Virus Taxonomy Profile: Picornaviridae. J. Gen. Virol. 2017;98:2421–2422. doi: 10.1099/jgv.0.000911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000911</ArticleId><ArticleId IdType="pmc">PMC5725991</ArticleId><ArticleId IdType="pubmed">28884666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xu T., Tian H., Wu J., Yu X., Zeng L., Liu F., Liu Q., Huang X. Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis. Cancers. 2022;14:6206. doi: 10.3390/cancers14246206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14246206</ArticleId><ArticleId IdType="pmc">PMC9776948</ArticleId><ArticleId IdType="pubmed">36551691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan-Peregrino M., Garcia-Carbonero R., Laquente B., Álvarez R., Mato-Berciano A., Gimenez-Alejandre M., Morgado S., Rodríguez-García A., Maliandi M.V., Riesco M.C., et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J. Immunother. Cancer. 2021;9:e003254. doi: 10.1136/jitc-2021-003254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-003254</ArticleId><ArticleId IdType="pmc">PMC8578996</ArticleId><ArticleId IdType="pubmed">35149591</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson S.K., Classic K.L., Hadac E.M., Dingli D., Bender C.E., Kemp B.J., Russell S.J. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am. J. Roentgenol. 2009;192:279–287. doi: 10.2214/AJR.08.1205.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.08.1205</ArticleId><ArticleId IdType="pmc">PMC2710889</ArticleId><ArticleId IdType="pubmed">19098211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingorani S.R., Zheng L., Bullock A.J., Seery T.E., Harris W.P., Sigal D.S., Braiteh F., Ritch P.S., Zalupski M.M., Bahary N., et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J. Clin. Oncol. 2018;36:359–366. doi: 10.1200/JCO.2017.74.9564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.74.9564</ArticleId><ArticleId IdType="pubmed">29232172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen S.R., Quaranta V., Linford A., Emeagi P., Rainer C., Santos A., Ireland L., Sakai T., Sakai K., Kim Y.-S., et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat. Cell Biol. 2016;18:549–560. doi: 10.1038/ncb3340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3340</ArticleId><ArticleId IdType="pmc">PMC4894551</ArticleId><ArticleId IdType="pubmed">27088855</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelton R.A., Javed A., Zheng L., He J. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. J. Surg. Oncol. 2017;116:55–62. doi: 10.1002/jso.24642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.24642</ArticleId><ArticleId IdType="pubmed">28628715</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Hegde S., Knolhoff B.L., Zhu Y., Herndon J.M., Meyer M.A., Nywening T.M., Hawkins W.G., Shapiro I.M., Weaver D.T., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 2016;22:851–860. doi: 10.1038/nm.4123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4123</ArticleId><ArticleId IdType="pmc">PMC4935930</ArticleId><ArticleId IdType="pubmed">27376576</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedan S., Rojas J.J., Gros A., Mercade E., Cascallo M., Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 2010;18:1275–1283. doi: 10.1038/mt.2010.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.79</ArticleId><ArticleId IdType="pmc">PMC2911260</ArticleId><ArticleId IdType="pubmed">20442708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S., Pryshliak M., Pappritz K., Knoch K., Hazini A., Dieringer B., Schaar K., Dong F., Hinze L., Lin J., et al. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovasc. Res. 2020;116:1756–1766. doi: 10.1093/cvr/cvz259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz259</ArticleId><ArticleId IdType="pubmed">31598635</ArticleId></ArticleIdList></Reference><Reference><Citation>Girod M., Geisler A., Hinze L., Elsner L., Dieringer B., Beling A., Kurreck J., Fechner H. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320. Int. J. Mol. Sci. 2024;25:5618. doi: 10.3390/ijms25115618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25115618</ArticleId><ArticleId IdType="pmc">PMC11171967</ArticleId><ArticleId IdType="pubmed">38891807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>